Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think we just cross our fingers and see what the opening brings
Synovus Financial and Flagstar Bancorp -- Regional Banking's Top Turnaround Stories
print
Flagstar Bancorp (NYSE:FBC)
Intraday Stock Chart
Today : Tuesday 1 November 2011
It appears Regional Banks have finally put the worst of the recession behind them. For well over a year banks have posted improved credit quality and in the second half of 2011 have begun to report adequate loan growth. Analysts said business borrowers are increasingly relying on banks for financing that they used to get from the bond markets and elsewhere. The Bedford Report examines the outlook for companies in the Regional Banking sector and provides equity research on Synovus Financial Corporation (NYSE: SNV) and Flagstar Bancorp, Inc. (NYSE: FBC). Access to the full company reports can be found at:
www.bedfordreport.com/SNV
Point Blank Solutions Sold to an Affiliate of Sun Capital Partners
print
Point Blank Solutions (PN) (USOTC:PBSOQ)
Intraday Stock Chart
Today : Tuesday 1 November 2011
Point Blank Solutions, Inc. (OTC: PBSOQ), a leader in the field of protective body armor, today announced that an affiliate of Sun Capital Partners, Inc. has emerged as the successful bidder for substantially all of the Company's operating assets through a 363 bankruptcy sale. Sun Capital is a leading private investment firm specializing in leveraged buyouts and investments in market-leading companies. The sale was approved by the U.S. Bankruptcy Court in Delaware on October 28, 2011.
"A new chapter in our corporate evolution has begun, and we can now focus fully on executing our strategy and exceeding the expectations of our customers," said Jim Henderson, CEO of Point Blank Solutions. "I am proud of the collective efforts of the Point Blank team. We have all worked diligently to move our business forward through this reorganization process. We are especially pleased to have the support of Sun Capital, given their strong track record, their understanding of our industry, and their commitment to growing our business."
"We welcome the Point Blank management team and employees to the Sun Capital family, and are very excited about the future possibilities," said Brian McGee, Vice President at Sun Capital Partners. "With Protective Products Enterprises, Paraclete, and now Point Blank Body Armor and PACA Body Armor, Sun Capital is proud to own some of the most trusted brands in the industry. These companies have great potential, offer unique and differentiated products, and are privileged to serve some of the world's most important customers."
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
print
Alexza (NASDAQ:ALXA)
Intraday Stock Chart
Today : Friday 28 October 2011
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report financial results for the quarter ended September 30, 2011, on Monday, November 7, 2011, following the close of the U.S. financial markets. On Monday, November 7, at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time, the Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results. The conference call, live webcast and archived replay are open to all interested parties.
First California Continues Earnings Momentum With 2011 Third Quarter Net Income of $2.5 Million
print
First California Financial Grp., Inc. (MM) (NASDAQ:FCAL)
Intraday Stock Chart
Today : Thursday 27 October 2011
First California Financial Group, Inc. (NASDAQ: FCAL), the holding company of First California Bank, today reported third quarter net income of $2.5 million compared with $64,000 for the same quarter a year ago. Net income available to common shareholders was $900,000, or $0.03 per diluted share, which was after dividends of $1,615,500 on the preferred stock series B and series C shares. A year ago, the Company had a third quarter net loss available to common shareholders of $249,000, or $0.01 per share, which was after a $312,500 cash dividend on the series B preferred shares.
"Our strong earnings were the result of successful implementation of initiatives designed to leverage the capital that we raised in 2010 by acquiring strategic assets and expanding our operating platform," said C. G. Kum, president and chief executive officer of First California Financial Group. "These initiatives, which included the acquisition and integration of two FDIC assisted transactions and the EPS division as well as the addition of new lending teams, contributed to improvement in our top-line revenues, growth in core earnings, higher net interest margin and lower efficiency ratio. Moreover, with our ongoing success in improving asset quality, we continue to lower our exposure to problem assets."
Looking forward to earnings coming out after close.
First California to Report 2011 Third Quarter Results and Host Conference Call on Thursday, October 27, 2011
print
First California Financial Grp., Inc. (MM) (NASDAQ:FCAL)
Intraday Stock Chart
Today : Monday 24 October 2011
First California Financial Group, Inc. (NASDAQ: FCAL) today announced that the company will issue its 2011 third quarter financial results before the market opens on Thursday, October 27, 2011, and host a conference call that same day at 11 a.m. Pacific (2 p.m. Eastern) to review the company's financial performance and answer questions.
Investment professionals are invited to participate in the live call by dialing 877-317-6789 (domestic), 866-605-3852 (Canada) or 412-317-6789 (international) and requesting the First California conference call. The call will also be available through a live, listen-only audio Internet broadcast at www.fcalgroup.com. Listeners are encouraged to visit the Web site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The call will be archived on the same Web site for one year. A telephonic replay of the call will be available one hour after the end of the conference through November 9, 2011 by dialing 877-344-7529 (domestic) or 412-317-0088 (international) and entering replay passcode 10005826.
Radian to Webcast Third Quarter Conference Call on November 1, 2011
print
Radian (NYSE:RDN)
Intraday Stock Chart
Today : Friday 21 October 2011
Radian Group Inc. today announced that it will hold a conference call on Tuesday, November 1, 2011, at 10:00 a.m. Eastern time to discuss the company’s third quarter 2011 results, which will be announced prior to the market open on the same day.
The conference call will be broadcast live over the Internet at http://www.radian.biz/page?name=Webcasts or at www.radian.biz. The call may also be accessed by dialing 800-288-8960 inside the U.S., or 612-332-0107 for international callers, using passcode 221288 or by referencing Radian.
I would love to hear an explaination on what happened yesterday with 500 shares sold at .012 cents, thats $6 freakin dollars. Is this the MM doing some BS,, or some meatball selling 500 shares and losing money and making this price drop like it did, am I the only one annoyed by this? or should I not be
thanks
awesome volume today as well
great start, can it hold?
awesome finish to a beautiful day, keep going fbc
Hang tough, we will be fine
My .75 I called is looking better, going to be time to buy soon
I think this will be moving right up untill earnings on the 26th
Nice upward movement today
why hasnt FCAL traded today, what am i missing???????????
Alphatec Spine to Hold 3Q 2011 Financial Results Investor Call
print
Alphatec Holdings, Inc. (MM) (NASDAQ:ATEC)
Intraday Stock Chart
Today : Thursday 13 October 2011
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a leading medical technology company involved in the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders, with a focus on treating conditions affecting the aging spine, announced today that it will hold an investor call on Tuesday, November 1, 2011 to discuss the Company's third quarter 2011 financial results.
Alphatec Spine will host this webcast and conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, November 1, 2011. The dial-in numbers are (877) 556-5251 for domestic callers and (720) 545-0036 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.alphatecspine.com. Participating in the call will be Dirk Kuyper, President and Chief Executive Officer, Michael O'Neill, Chief Financial Officer, and Ebun S. Garner, Esq., General Counsel.
After the live webcast the call will remain available on Alphatec Spine's website for at least 30 days following the presentation.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its subsidiary, Scient'x S.A., via a direct sales force in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa, South America and Latin America. In Asia and Australia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc., and through Scient'x's distributors in China, Korea and Australia.
The Alphatec Holdings, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3520
CONTACT: Michael O'Neill
Chief Financial Officer
Alphatec Spine, Inc.
(760) 494-6746
investorrelations@alphatecspine.com
Westwicke Partners
Lynn C. Pieper
(415) 202-5678
lynn.pieper@westwicke.com
On facebook they mentioned it was far east as mississippi. wanna see if its going to make its way to the east coast anytime soon
wow my spirts are up again, we have a little buying life
Flagstar Bancorp, Inc. (NYSE: FBC) today released instructions for its third quarter 2011 earnings call, which will be held on Wednesday, October 26, 2011, from 11 a.m. to noon (ET
really thought it would pop a bit
should be an interesting day
Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Lat...
print
Alexza (NASDAQ:ALXA)
Intraday Stock Chart
Today : Thursday 6 October 2011
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer International, S.A., announced today that they entered into a commercial partnership for Adasuve™ (Staccato® loxapine). ADASUVE is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and will be Alexza's partner in the registration, distribution and promotion of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. Alexza plans to file the ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the second half of 2011. ADASUVE is being developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
"The treatment of agitation in patients with schizophrenia or bipolar disease continues to evolve in the field of psychiatry, and we believe that ADASUVE could represent an important new therapeutic option for these patients," said Thomas B. King, Alexza's President and CEO. "Given Grupo Ferrer's extensive experience registering and selling specialty pharmaceuticals in Europe and Latin America, and their ability to share our longer-term vision for ADASUVE, we believe they represent an ideal multi-region partner for Alexza as we execute our global commercialization strategy."
"We welcome the opportunity to bring this innovative technology to our markets," said Mr. Jordi Ramentol, CEO of Grupo Ferrer. "ADASUVE fits perfectly into our specialty pharmaceutical portfolio. We strongly believe that the unique therapeutic benefits ADASUVE provides will capture physicians' and patients' interest, and establish it as an important new tool in the treatment of agitation."
Under the agreement, Alexza will receive an upfront payment of $10 million. Alexza is eligible to receive additional milestone payments based upon regulatory approvals, individual country commercial sales initiation and cumulative net sales targets. Alexza will be responsible for filing the ADASUVE MAA with the EMA. Grupo Ferrer will be responsible for all subsequent regulatory filings in the countries in its territories, as well as any required pricing and reimbursement filings and approvals. Assuming regulatory approvals are obtained, Grupo Ferrer will exclusively distribute, market and sell ADASUVE in the designated territory. Alexza will be the exclusive supplier of ADASUVE to Grupo Ferrer for all of its commercial sales, at a per-unit transfer price.
About ADASUVE (Staccato loxapine)
ADASUVE is an anti-agitation therapeutic that combines Alexza's proprietary Staccato system with loxapine, an antipsychotic drug. Loxapine is currently available in oral and other formulations, inside and outside of the U.S. and European Union. The Staccato system is a hand-held, single-dose inhaler that delivers a drug aerosol to the deep lung that results in IV-like pharmacokinetics and rapid systemic effects.
As an easy-to-use, non-coercive and highly reliable inhaled therapeutic that has been shown to produce a rapid reduction in agitation, Alexza believes that ADASUVE meets the three key attributes for the treatment of acute agitation as specified in the American Association of Emergency Psychiatrists' Expert Consensus Guidelines for the Treatment of Behavioral Emergencies: speed of onset, reliability of medication delivery and patient preference. Similarly, the National Institute for Health and Clinical Excellence (NICE) Clinical Practice Guidelines describe an ideal treatment for agitation as having a low level of side effects and a rapid onset of action, and that injections should be administered only in exceptional circumstances.
About the Staccato System
Alexza's proprietary Staccato system was rationally designed to optimally treat acute and intermittent conditions. A single breath triggers vaporization and delivers a dose of excipient-free aerosolized, highly bioavailable drug deep into the lungs, where it is quickly absorbed into the blood stream to begin providing therapeutic effect. The Staccato system delivers medication that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
The Staccato system is unique among inhalers because it uses no excipients, requires no special breathing maneuvers and there are no controls to deal with. When the patient draws a single normal breath through the Staccato device, the substrate surface instantly heats to create a condensation aerosol of optimally-sized particles of drug that are drawn into the patient's lungs. The entire Staccato system actuation and drug delivery occur in less than one second. The system produces a consistently high emitted pre-set dose, regardless of the patient's breathing pattern.
Alexza has screened more than 400 drug compounds and more than 200 drug compounds exhibit initial vaporization feasibility with the Staccato system. Since the filing of the Company's first IND in 2004, Alexza has dosed more than 2,600 patients and subjects with its Staccato technology, in 22 different clinical trials under six different INDs for Staccato-based product candidates.
Conference Call Information
Alexza will host a conference call on Thursday, October 6, 2011, at 9:00 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call and replay are open to all interested parties.
To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also register to avoid pre-call delays at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=196151&eventID=4213500.
To access the live conference call via phone, dial +1.800.299.7928. International callers may access the live call by dialing +1.617.614.3926. The reference number to enter the call is 72215077.
The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at +1.888.286.8010 for domestic callers or +1.617.801.6888 for international callers. The reference number for the replay of the call is 96463030.
About Grupo Ferrer
Grupo Ferrer is a privately-held European R&D-based pharmaco-chemical and medical device company headquartered in Barcelona, Spain. Founded in 1959, the group encompasses today 45 companies developing its activities in Europe, Latin America, Africa, Middle East, Asia and the United States. In total, Grupo Ferrer's human healthcare products are being commercialized in 93 countries through 26 direct subsidiaries (including Joint Ventures) and 70 partners and distributors.
Grupo Ferrer carries out activities throughout the full value-chain of the pharma business, from R&D to international marketing, including fine chemicals development and both raw material and pharmaceutical product manufacturing. For this purpose, Grupo Ferrer has research centres in Spain and Germany, as well as manufacturing sites in Europe and Latin America.
Grupo Ferrer's regulatory expertise has resulted in more than 800 active registration dossiers worldwide, including high added-value products for orphan and life-threatening diseases. The aim of Grupo Ferrer's corporate strategy is to establish alliances and long-term relationships with biotechnology and pharmaceutical companies within its strategic therapeutic areas. The company holds a long track record of agreements signed with big multinationals, as well as with medium size pharmaceutical companies and small biotech or R&D-based companies.
The company has experience with high value-added products, for very specific indications (i.e., Remodulin® (Treprostinil) for PPH, Egrifta® (tesamorelin) for HIV lipodistrophy) that may have specific requirements in terms of administration (injectables, subcutaneous pumps, etc.).
For more information about Grupo Ferrer, visit the Company's web site at www.ferrergrupo.com.
About Alexza Pharmaceuticals, Inc.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)
ADASUVE (Staccato loxapine), Alexza's lead program, is being developed for the rapid treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009. In October 2010, the Company received a Complete Response Letter from the FDA regarding the application. The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011. The ADASUVE NDA was resubmitted on August 4, 2011, and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012. The FDA has indicated that it will likely present the ADASUVE application to an Advisory Committee during the review period. The Company also plans to file the ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the second half of 2011.
For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.
Safe Harbor Statement
This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the CRL, the timing of the FDA's review of the NDA and the eventual prospects that ADASUVE will be approved for marketing. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
Alphatec Spine Announces Successful Resolution of FDA Warning Letter
print
Alphatec Holdings, Inc. (MM) (NASDAQ:ATEC)
Intraday Stock Chart
Today : Wednesday 5 October 2011
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that it has resolved a Warning Letter that it had previously received from the U.S. Food and Drug Administration for the Company's Carlsbad, CA, facility.
The FDA issued the Warning Letter on June 21, 2010 in connection with deficiencies in the response letter sent by the Company to the FDA in connection with a FDA inspection that occurred in February 2010.
Subsequent to a follow-up audit of the Company's facility, the FDA issued a close-out letter dated September 28, 2011. In this letter, the FDA stated that the Company has resolved all the deficiencies contained in the Warning Letter.
"The successful resolution of the Warning Letter demonstrates our firm commitment to maintaining a robust quality system throughout our organization," said Dirk Kuyper the Company's President and CEO.
Point Blank Solutions Receives $30 Million in Orders to Support U.S. Military and Government OperationsLast update: 10/5/2011 8:00:00 AMPOMPANO BEACH, Fla., Oct. 5, 2011 /PRNewswire via COMTEX/ -- Point Blank Solutions, Inc. (otc-bb:PBSO), a leader in the field of protective body armor, today announced that Point Blank Body Armor, the Company's wholly owned subsidiary, has received multiple orders totaling approximately $30 million for the production of Outer Tactical Vest ("OTV") ballistic panel kits and related ballistic components. Products produced by the Company will be used to support U.S. Military and Government operations and the Company expects to begin production in the fourth quarter of 2011. Commenting on the announcement, Jim Henderson, Chief Executive Officer and Chairman of the Board stated, "Over the past year, we have made significant improvements in our manufacturing capabilities, improved our supply chain and industry relationships and greatly enhanced our product design and engineering initiatives. All of these steps have enabled us to remain a key supplier of protective solutions for the U.S. Military and Government, and have contributed to our growth in other areas of our business, most notably the domestic law enforcement market. We look forward to continuing to meet the needs of the Government and all of our customers, providing the most innovative body armor solutions the industry has to offer." Point Blank Body Armor continues to produce solutions for the U.S. Military and Government and has generated approximately $50 million in sales year-to-date. With current backlog commitments, the Company expects 2011 sales for this channel, both direct and through its strategic teaming partners, to exceed $75 million.
Alexza Pharmaceuticals Raised To Mkt Outperform From Mkt Perform By JMP Securities >ALXA
Interesting, 5000 buy yesterday at .019 ... today 5000 at .019 and level 2 still says another 5000 at .019. Thought it would move up
wow up 4 cents, biggest movment in a while, hope it last
Thanks for sharing
What a dead board now, did someone die?
UPDATE: New Bond Insurer Concept AdvancesLast update: 9/26/2011 1:52:55 PM--National League of Cities and Radian to explore possible launch of new mutual bond insurer. --Aims to make borrowing cheaper for states and localities. --Only one active muni bond insurer remains in market. (adds details throughout)
By Andrew Ackerman
Of DOW JONES NEWSWIRES
New Bond Insurer Concept AdvancesLast update: 9/26/2011 12:35:46 PM
By Andrew Ackerman
Of DOW JONES NEWSWIRES
WASHINGTON (Dow Jones)--The National League of Cities and mortgage guarantor Radian Group Inc. (RDN) announced Monday they are partnering to explore the formation of a new mutual bond insurance company for debt sold by states and local governments. The agreement is designed to make it easier for municipalities to access the credit markets in the $2.9 trillion municipal bond market. As a mutual insurer, the Radian-managed company would be owned by the issuers who purchase the insurance. NLC sought up to $1.5 billion in federal seed money to get the idea off the ground nearly three years ago. But the group began looking to raise private capital in the face of reluctance by the federal government to participate. Several aspirants have fought to break into the bond insurance market to replace guarantors like MBIA Inc. (MBI) and Ambac Financial Group Inc. (ABKFQ) that saw their ratings collapse during the financial crisis because of their exposure to tainted mortgage-backed securities. But few firms have successfully launched new companies. And none have been able to maintain top flight ratings from all three major ratings firms. "A mutual bond insurance company with a public finance book of business would restore capacity that was lost," David Beidler, president of Radian's Asset Assurance Inc. unit, said in the statement. "The mutual insurance company structure, with the issuers as members, offers insurance to bondholders that the company will not deviate from its public finance mission." Insurers collect a portion of bond principal at the time of issuance in exchange for a contractual agreement to cover any missed payments over the life of the bond. The agreement with Radian assumes the company would be backed as a private-public partnership. In earlier iterations, NLC proposed private capital in a first-loss position, meaning it would be used first to pay claims. Neither NLC or Radian would say how much capital they are seeking to raise privately. In June, Radian paid $82 million to acquire a New York based shell-company called Municipal and Infrastructure Assurance Corp. The shell company was founded by Australian investment firm Macquarie Group in unsuccessful big to start a municipal bond insurer of its own. Though it had not written any business, the shell company won regulatory approval to do so in 36 states plus the District of Columbia. Radian's muni insurer in 2008 was forced to stop writing public finance guarantees to prop up a sister's company's mortgage insurance business. Though Warren Buffett's Berkshire Hathaway Inc. (BRKA, BRKB) set up a municipal bond insurance company in late 2007, it stopped underwriting new policies largely because perceived risk. Specifically, Buffett argued a troubled municipality is more likely to default on its obligations if there is a bond insurer sitting between it and the bondholder. -By Andrew Ackerman, Dow Jones Newswires; 202-569-8390; andrew.ackerman@dowjones.com (END) Dow Jones NewswiresSeptember 26, 2011 12:35 ET (16:35 GMT)
Radian and the National League of Cities Announce Agreement to Explore Formation of a New Mutual Bond Insurance CompanyLast update: 9/26/2011 8:00:04 AMPHILADELPHIA, Sep 26, 2011 (BUSINESS WIRE) -- Radian Group Inc. and the National League of Cities, a non-profit association of cities and state municipal leagues (NLC), today announced an agreement between NLC and Radian's financial guaranty subsidiary, Radian Asset Assurance Inc., to explore the formation of a new public finance mutual bond insurance company. NLC began to pursue the creation of the first-ever mutual bond insurance company in response to the need for expanded capacity in the bond insurance industry. Donald J. Borut, NLC Executive Director, praised Radian for its willingness to work with NLC in pursuing this new and compelling opportunity. Borut said that "Radian is an established and experienced bond insurer that has the resources, people, infrastructure, transparency, and vision to help NLC, its members, and the thousands of local governmental issuers that access the municipal bond market each year." S.A. Ibrahim, Radian's Chief Executive Officer, added, "We are delighted to work with NLC, whose leadership, expertise and reputation in supporting municipal issuers are unmatched. We look forward to the opportunity to leverage Radian's knowledge of municipal bond insurance for NLC members." The objective of creating a next generation bond insurer is to provide bondholders with a superior level of credit enhancement, while allowing municipal issuers to benefit from lower-cost financing. "A mutual bond insurance company with a public finance book of business would restore capacity that was lost in recent years," noted David Beidler, President of Radian Asset Assurance Inc. "More importantly, the mutual insurance company structure, with the issuers as members, offers assurance to bondholders that the company will not deviate from its public finance mission." While Radian and NLC are still working on the details of the structure, they anticipate it will involve the support of private capital from third-party investors.
kinda funny, 3 trades on pfob today, 2 sells at 120,000 and 2500, and 0ne buy at 20,000 and the stock goes up, we will never be able to figue it out
Radian Positions Company to Compete in Current Market Environment
print
Radian (NYSE:RDN)
Intraday Stock Chart
Today : Thursday 22 September 2011
Radian Group Inc. today announced that it has re-aligned its operational structure in order to compete more effectively as a leading private mortgage insurer. The primary objective is to focus the company’s resources on sales and other core functions to grow profitable new business while aligning its support services to the reduced mortgage market volume expected in the near term. The re-alignment included a workforce reduction of approximately 7 percent of Radian’s corporate and mortgage insurance staff.
“Our top priority at Radian is to write as much new, high-quality mortgage insurance business as possible,” stated Teresa Bryce Bazemore, president of Radian Guaranty Inc. “We are taking advantage of every opportunity to grow our business, including increasing our sales presence in key markets across the country and signing more than 150 new customers over the past year.”
“At Radian, we have been successful in increasing our market share and broadening our customer base. Yet our operational structure was built for a mortgage market that is much larger than today’s reality,” added Radian’s Chief Executive Officer S.A. Ibrahim. “We will continue to add resources where they are most needed to support our customers, particularly in sales.”
What do u think will happen next? The price just keeps going down, not even tring to come up
Point Blank Solutions' First Tri-Compliant Ballistic Armor Package Passes National Institute of Justice ("NIJ") TestingLast update: 9/14/2011 11:00:00 AMNew FIIIA ballistic package is the latest NIJ .06 ballistic system that meets FBI and DEA testing protocols with a 9mm 124gr FMJ V-50 exceeding 2,000 feet per second (fps) POMPANO BEACH, Fla., Sept. 14, 2011 /PRNewswire via COMTEX/ -- Point Blank Solutions, Inc. (otc pink sheets:PBSO), a leader in the field of protective body armor, today announced the availability of its newest FIIIA ballistic package for the federal and commercial markets. This latest FIIIA solution has been determined to comply with the industry's most stringent testing protocols for body armor performance - the National Institute of Justice (NIJ) Standard-0101.06. Additionally, the FIIIA package exceeds the recently revised testing requirements for the Federal Bureau of Investigation (FBI) and Drug Enforcement Agency (DEA), as verified by multiple, independent test labs. The FIIIA is the latest addition to Point Blank's family of body armor solutions and will headline the Company's offering to the federal market. It will also be available for global customers, including Military and Government, and law enforcement, corrections and private security agencies. It is specially designed to address the strategic needs of officers' most critical missions - providing the highest level possible of ballistic and trauma protection in a more comfortable body armor system. Furthermore, it has been rigorously tested based on the NIJ's standard Level IIIA bullets (.357 SIG TMJ FN and .44 MAG SJHP), the FBI's controlled projectile and most prolific threat (9mm 124gr TMJ RN) and the DEA's MIL-STD-662F fragmentation. Results consistently show that the system delivers unparalleled protection even in the most extreme environments. Sam White, EVP of Business Development at Point Blank Solutions stated, "Our latest FIIIA ballistic package is the culmination of more than a year spent working with our supply chain partners to develop a lightweight, flexible and high-performing solution that meets the needs of multiple market segments. We are especially proud of this latest advancement as we believe, based on independent testing data, that the performance characteristics are unmatched by any ballistic solution in market." Preliminary data compiled by the National Law Enforcement Officers Memorial Fund (NLEOMF) show a total of 98 federal, state and local law enforcement officers died during the first half of 2011 (January 1, 2011 to June 30, 2011). This represents a 14% increase over the 86 officer fatalities during the same time in 2010. Firearms-related fatalities reached a 20-year high, increasing 33% from 30 to 40 officers shot and killed in 2011. The latest NIJ. 06 standard establishes tougher performance mandates and test methods for the ballistic resistance of personal body armor, with the goal of improving and ensuring that the highest possible life-protecting capabilities are provided. In addition to the NIJ standardized testing, the FBI and DEA Body Armor Test Protocols are designed to place further stringent demands on body armor. These tests are intended to simulate threats/conditions that FBI and DEA personnel are likely to face. Mr. White continued, "The FIIIA package has a v50 of over 2,000 feet per second and provides unmatched protection against both fragmentation and bullets. We believe this will be a solution of choice for our customers and prospects, and look forward to showcasing this and other ballistic and carrier designs throughout the year. Our goal remains to provide the industry with the most technologically-advanced solutions the industry has to offer, which is especially important given escalating threats our servicemen, officers and agents are facing today."
where has color or ccc been, whats going on, anyone
see no more cheap shares to be had, you have to pay the price now, to late for cheap shares